Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide effects on glycemic control, gut microbiota, and metabolites in overweight or obese adults with newly diagnosed type 2 diabetes
ChiCTR1900023036Phase 4Not yet recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Jun 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of liraglutide in type 2 diabetes mellitus (T2DM), sponsored by Southern Medical University Zhujiang Hospital. Primary endpoint: Glycated hemoglobin. Planned start Jun 2019; status: not yet recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR1900023036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023036.